

Navigating Access for NEMLUVIO

for Adults With Prurigo Nodularis (PN)

Disclaimer: Galderma Laboratories, L.P. cannot guarantee insurance coverage or reimbursement. Coverage or reimbursement may vary significantly by payer, plan, patient, and setting of care. It is the sole responsibility of the health care provider (HCP) to ensure the accuracy of all statements made in seeking coverage and reimbursement for an individual patient.

IMPORTANT SAFETY INFORMATION

Indication: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor antagonist indicated for the treatment of adults with prurigo nodularis. **Contraindication:** Known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO. **Warnings/Precautions:** Hypersensitivity reactions have been reported with NEMLUVIO use. If a clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO. **Adverse Events:** Most common adverse reactions (incidence ≥1%) are headache, dermatitis atopic, eczema, and eczema nummular.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see accompanying Prescribing Information or click here for full [Prescribing Information](#).

Table of Contents

The purpose of this resource is to equip you with information to support patient access to NEMLUVIO. It includes information on how to get patients started on treatment, navigating common payer restrictions with a focus on prior authorizations, and best practices for appealing a specific denial.

3 Getting Started

5 Navigating Access

Prior Authorization	5
Step Therapy	9
Formulary Exclusion	9
Quantity Limits	10

11 Appeals

13 Sample Forms

Letter of Medical Necessity	13
Letter of Appeal	15
Patient Letter	17

19 Billing & Coding


20 Patient Support

Please see Important Safety Information on page 1 and accompanying Prescribing Information or click here for full [Prescribing Information](#).



Getting Started

Pathway to initiate NEMLUVIO



Enrollment Form

Every patient prescribed NEMLUVIO is encouraged to enroll in GPS for NEMLUVIO by completing a NEMLUVIO Enrollment Form with the aid of your office. Enrolling the patient in GPS for NEMLUVIO helps support you and your patient by streamlining the benefits verification and PA processes, and may reduce your operational workload. Please scan or click the code to the right to access the NEMLUVIO [Enrollment Form](#).



Galderma Field Access Managers

The Galderma Field Access Managers play an important role in providing support and education to reduce non-clinical barriers for patient access. They can help with:

- Providing in-depth overview of services
- Navigating NEMLUVIO Enrollment Forms
- Benefits investigation and PA/appeal requirements
- Streamlining the Quick Start process and patient onboarding to NEMLUVIO

*The NEMLUVIO Enrollment Form serves as the prescription for NEMLUVIO.
HCP, health care provider; PA, prior authorization; PN, prurigo nodularis; SP, specialty pharmacy.

Please see Important Safety Information on page 1 and accompanying Prescribing Information or click here for full [Prescribing Information](#).



Getting Started (cont'd)

NEMLUVIO Network of Specialty Pharmacies (SPs)

To avoid delays in patient access, send the prescription to your office's chosen SP that is in NEMLUVIO's preferred network.

Please refer to the network of SPs for NEMLUVIO below. Our SP network provides enhanced service offerings so that you and your patients are supported throughout the entire NEMLUVIO access journey.

Specialty Pharmacy	Phone Number	Fax
AcariaHealth	800-511-5144	877-541-1503
Accredo Health Group, Inc.	866-839-2162	866-531-1025
Amber Specialty Pharmacy	888-370-1724	877-645-7514
BioPlus Specialty Pharmacy	800-292-0744	800-269-5493
Blue Sky Specialty Pharmacy	866-822-0103	833-898-3992
Centerwell Specialty Pharmacy	800-486-2668	877-405-7940
CVS Specialty	800-237-2767	800-323-2445
Kroger Specialty Pharmacy	888-355-4191	888-355-4192
Optum Specialty	855-427-4682	877-342-4596
Senderra	855-460-7928	888-777-5645

For more information on the specialty distribution network, please scan the code to the right or [click here](#) to access the *Distribution Fact Sheet for NEMLUVIO*



Please see Important Safety Information on page 1 and accompanying Prescribing Information or [click here](#) for full [Prescribing Information](#).



Prior Authorization (PA)

PA is a tool used by payers that requires a prescriber to provide information that the medication requested is appropriate for the patient. Drugs that require a PA will not be approved for payment until the conditions for approval of the drug are met.^{1*}

Examples of Common PA Criteria for PN

- Diagnosis of PN²
- Prescribed by or in consultation with a specialist, such as a dermatologist, allergist, or immunologist²⁻⁵
- Age within FDA label and indication³
- ≥ 20 nodular lesions^{2,5,6}
- Pruritus duration for ≥ 6 weeks^{5,6}
- History of failure, contraindication, or intolerance to previous PN treatment(s), such as phototherapy, topical corticosteroids, topical calcineurin inhibitors, methotrexate, or cyclosporine^{2,4,6,7}
- Patient is not receiving NEMLUVIO in combination with another biologic immunomodulator²

*PA does not guarantee reimbursement or payment.
FDA, United States Food and Drug Administration; PN, prurigo nodularis.

Please see Important Safety Information on page 1 and accompanying Prescribing Information or click here for full [Prescribing Information](#).




PA (cont'd)

PA Checklist

Payers often require certain information to process a PA request for drug coverage. This checklist will help you capture common necessary information from your patient to facilitate the processing of a PA request to the payer.

Step 1: Getting Started with GPS

- Complete the NEMLUVIO Enrollment Form, available [here](#)



Step 2: Clinical Records

- ICD-10 Diagnosis Code, see code for PN below, additional information is provided in the **Billing and Coding section**
Coding is a clinical decision; ensure you are coding to the highest level of specificity. The code shown below is only a suggestion and may vary by patient.
 - L28.1: Prurigo nodularis⁸
- Age of patient
- Weight of patient (when requesting a maintenance dose of 60 mg every 4 weeks for NEMLUVIO)
- Chart notes/documentation of diagnosis
 - Body location (i.e., head, hands, feet, face, and genital area)
 - Number of nodules (specify ≥ 20 nodules)
 - Duration/intensity of symptoms (specify ≥ 6 weeks of pruritus)
 - History/signs of repeated itch/scratch cycle
 - Quality of life impact
 - For continuation of therapy or reauthorization, documentation of improvement may be requested

Checklist continued on the next page.

GPS, Galderma Patient Services; ICD-10, International Classification of Diseases, Tenth Revision; PA, prior authorization; PN, prurigo nodularis.

Please see Important Safety Information on page 1 and accompanying Prescribing Information or click here for full [Prescribing Information](#).



PA (cont'd)

Step 3: Treatment History

Payers often require trial and failure of certain prescription or over-the-counter drugs prior to approving NEMLUVIO.

- List all products the patient has tried and failed. See examples below:


Examples of Previous Treatments	Required Information
<ul style="list-style-type: none"> <input type="checkbox"/> Phototherapy <input type="checkbox"/> Intralesional injections <input type="checkbox"/> Topicals <ul style="list-style-type: none"> <input type="radio"/> Topical corticosteroids <input type="radio"/> Topical calcineurin inhibitors <input type="radio"/> Topical PDE4 inhibitors <input type="checkbox"/> Oral immunomodulators <ul style="list-style-type: none"> <input type="radio"/> Methotrexate <input type="radio"/> Cyclosporine <input type="checkbox"/> Biologics <ul style="list-style-type: none"> <input type="radio"/> Dupilumab 	<ul style="list-style-type: none"> <input type="checkbox"/> Clinical documentation of the following: <ul style="list-style-type: none"> <input type="radio"/> Duration of therapy <input type="radio"/> Inadequate response <input type="radio"/> Adverse events experiences with treatment <p style="text-align: center;">OR</p> <input type="radio"/> Information regarding contraindication/intolerance <input type="radio"/> Discontinuation plan of current treatment(s) (i.e., if patient is currently being treated with a biologic but you are seeking approval to switch to NEMLUVIO)

Step 4: Submission

- Ensure all information is accurate and complete
- Submit the PA form and all chart notes/documentation via the payer's preferred method
NOTE: Please reference the payer's specific policy for that patient in order to ensure all required information is included

Checklist continues on next page.

Scan the QR code to the right or [click here](#) access the PA for Prurigo Nodularis (PN) Patients.



PA, prior authorization; PDE4, phosphodiesterase 4.

Please see Important Safety Information on page 1 and accompanying Prescribing Information or [click here](#) for full **Prescribing Information**.



PA (cont'd)

Reauthorization

A reauthorization may be required after a specified time period following initial PA approval. There are often plan-specific requirements to show evidence of clinical response, such as improvement from baseline measurements (ie, number of nodules, PP-NRS, IGA) and supporting documentation to provide evidence of the therapy's efficacy. Payers may have specific forms for reauthorization.

Common Reasons for a PA Denial

- Patient does not meet clinical criteria for approval
- A need for additional information, such as missing or incorrect chart notes/documentation
- Original submission did not include prior treatments tried/failed, reasons for failure, or contraindications to alternative treatments
- Patient is currently using a contraindicated medication or another advanced therapy without a discontinuation plan
- Age outside of FDA-approved label
- For reauthorizations, denials may occur if demonstrated efficacy is not communicated

**If a PA is denied, an appeal can be submitted.
Please refer to the [Appeals](#) section for more information.**

FDA, United States Food and Drug Administration; GPS, Galderma Patient Services; IGA, Investigator's Global Assessment; PA, prior authorization; PP-NRS, Peak Pruritus Numeric Rating Scale.

Please see Important Safety Information on page 1 and accompanying Prescribing Information or click here for full [Prescribing Information](#).



Navigating Access

Step Therapy

Step therapy requires the use of a first-line drug before the approval of another medication.¹



Best Practices

- Review the payer's criteria
- Provide documentation to support medical necessity
- Include medications patient has tried and failed, the duration of therapy, and reason(s) why those treatments are no longer an option for the patient

Formulary Exclusion

A formulary exclusion list includes drugs that an insurer, payer, or pharmacy benefits manager does not cover.⁹



Best Practices

- The HCP may request a formulary exception (also known as a medical exception) for an excluded drug¹⁰
- The HCP may need to provide which drugs on the payer's formulary the patient has tried and failed or has a contraindication to

HCP, health care provider.

Please see Important Safety Information on page 1 and accompanying Prescribing Information or click here for full [Prescribing Information](#).



Navigating Access (cont'd)

Quantity Limits

A payer may limit drug coverage to quantities that are consistent with FDA-approved durations or dosing.¹

- For loading doses, a drug and quantity PA may be required
- Most payers limit each fill to a 28-day supply while others may allow a 3-month supply



Best Practice

- The pharmacy may contact the physician to change the prescription, or the physician may choose to submit a quantity limit exception request if the prescription as written is medically necessary¹¹

In adults with PN that are ≥ 90 kg,

**2 subcutaneous injections
of NEMLUVIO 30 mg
is the approved dosing schedule.¹²**

FDA, United States Food and Drug Administration; PA, prior authorization; PN, prurigo nodularis.


Please see Important Safety Information on page 1 and accompanying Prescribing Information or click here for full [Prescribing Information](#).



Appeals

If a request for a prior authorization (PA) or a formulary exception is denied, your office or patient may consider submitting an appeal. An appeal is a request to your patient’s payer to consider additional information for approval.

Overview of Appeals Process



Typically, denials and appeals are processed within 7 days, but timing may vary based on the payer. Review individual payer documents for specific timing.

*Prior to appeal, check with payer to see if they offer a peer-to-peer review.

†Note: Most plans will not allow resubmission of PA within a certain time frame, especially managed Medicaid plans.

Please see Important Safety Information on page 1 and accompanying Prescribing Information or click here for full [Prescribing Information](#).



Appeals (cont'd)

Appeals Checklist

Step 1: Confirm Appeal Process With the Payer

- Review the reason for denial; ensure you understand fully prior to continuing with the appeal
- Review the payer's appeal process to determine the following:
 - Specific form required by the payer
 - Required or preferred method of submission (over the phone, in writing, etc.)
 - Information that must be included in the appeal
 - Anticipated timeline for review and response
 - How the plan will communicate the decision
- Notify the patient if your office may need their involvement
- Reach out to your Galderma Field Access Manager for assistance with the appeal process if needed

Step 2: Submission

- Complete and submit appeal request
 - Complete the required documentation
 - Review the appeal request for accuracy and completeness
 - Submit the required documentation
- Follow up
 - Provide any additional documentation as requested within the required time frame

Step 3: Document Decision

- If the appeal is approved, document the medical exception or PA number to include within the patient's chart
- If the appeal is denied, document the date the denial was received and the reason for denial. Determine if an additional appeal will be requested

PA, prior authorization.

Please see Important Safety Information on page 1 and accompanying Prescribing Information or click here for full [Prescribing Information](#).



Letter of Medical Necessity

A **Letter of Medical Necessity** is a written explanation from the HCP that describes the summary of treatment and rationale for why NEMLUVIO is clinically necessary for the patient. These letters should be presented in a concise manner while also making as strong an argument as possible.

Considerations and Best Practices for Writing a Letter of Medical Necessity

- Review the payer's coverage policy and provide background on your patient's condition
- Be sure to clearly state your patient's individual situation and justify why the prescribed therapy is the most appropriate treatment
- Present all required information such as documentation of all criteria your patient meets and a clear rationale for any they do not meet
- Include clinical justification, copies of relevant clinical data, and impact on quality of life to support your decision
- Submit the letter (on your office letterhead) as requested by your patient's payer along with the PA or formulary exception request
- Monitor the status of your request and follow up as needed

Please see the following page for a sample Letter of Medical Necessity. This is for informational purposes only and to be used as an example of what may be required or helpful when submitting a request to a patient's payer. Use of this information does not constitute medical or legal advice and does not guarantee reimbursement for coverage. It is not intended to be a substitute for the independent clinical decision of the prescribing HCP.

HCP, health care provider; PA, prior authorization.

Please see Important Safety Information on page 1 and accompanying Prescribing Information or click here for full [Prescribing Information](#).



Letter of Medical Necessity (cont'd)

[Date]

SAMPLE LETTER

[Patient's name]
[Date of birth]
[Case identification]

Re: Letter of Medical Necessity for NEMLUVIO® (nemolizumab-ilto)

To Whom It May Concern:

I am a [board certified dermatologist] with [#] years of experience writing to provide additional information to support the need for [patient's name]'s NEMLUVIO [dose and directions] for the treatment of adults with prurigo nodularis (PN). In brief, treatment with NEMLUVIO is medically necessary based on the patient's confirmed diagnosis of PN, severity of symptoms, impact to quality of life, and ineffective response to prior treatments. This letter includes the patient's medical history, previous treatments, and evidence from published articles that support the need for NEMLUVIO.

Diagnosis and Medical History

Patient Demographics
Patient diagnosis: [include ICD-10 diagnosis code]
Disease severity: [include information such as number of nodules, duration of pruritus, and history or signs of repeated itch-scratch cycle]
Quality of life measures: [include information such as patient occupation and impact on daily activities, i.e., school bus driver who is not getting enough sleep]

Treatment History		
Drug/dose	Treatment dates	Reason(s) for discontinuation or contraindication

NEMLUVIO is one of only two FDA-approved treatments for PN and has been shown to be safe and effective based on the two OLYMPIA phase 3 trials. In the clinical trials, NEMLUVIO monotherapy was administered every 4 weeks in adults with moderate-to-severe PN, which my patient suffers from. NEMLUVIO showed significant and rapid itch relief, skin clearance, and reductions in sleep disturbance compared to placebo in these trials, which my patient could benefit from.^{1,2}

[Summarize treatment recommendation here].

Please feel free to contact me, at [office phone number] for any additional information you may require. We look forward to receiving your timely response and approval of this claim.

Sincerely,

[Physician's name and signature, medical specialty, and contact information]

Attachments: [include list of supporting information provided with letter such as patient medical records, referenced publications, and/or NEMLUVIO Prescribing Information]

References:

1. NEMLUVIO. Prescribing Information. Galderma Laboratories, L.P.; August 2024.
2. Kwatra SG, et al. N Engl J Med. 2023;389(17):1579-1589.

US-NPN-2400024 (08/24)

Scan the QR code to the right or [click here](#) to download the sample letter as a Word document to customize for your patient.



Please see Important Safety Information on page 1 and accompanying Prescribing Information or [click here](#) for full **Prescribing Information**.



Letter of Appeal

A **Letter of Appeal** is a document that requests a payer to reconsider its initial decision to deny coverage for NEMLUVIO. These letters are tailored to the specific needs of the patient and describe why NEMLUVIO is the most appropriate treatment option for the patient. These letters should be presented in a concise manner while also making as strong an argument as possible.

Considerations and Best Practices for Writing a Letter of Appeal

- Review the payer's denial and clearly state your reason for disagreeing with the denial
 - Provide background on your patient's condition
 - Be sure to clearly state your patient's individual situation and justify why the prescribed therapy is the most appropriate therapy option
 - Present all required information such as documentation of all criteria your patient meets and a clear rationale for any they do not meet
- Include clinical justification and copies of relevant clinical data to support your decision
- Submit the letter (on your office letterhead) as requested by your patient's payer
- Monitor the status of your appeal and follow up as needed

Please see the following page for a sample Letter of Appeal. This is for informational purposes only and to be used as an example of what may be required or helpful when responding to a request from a patient's payer. Use of this information does not constitute medical or legal advice and does not guarantee reimbursement for coverage. It is not intended to be a substitute for the independent clinical decision of the prescribing health care provider.

Please see Important Safety Information on page 1 and accompanying Prescribing Information or click here for full [Prescribing Information](#).



Letter of Appeal (cont'd)

[Date]

[Patient's name]
[Date of birth]
[Case identification]

SAMPLE LETTER

Re: Appeal of Coverage Denial for NEMLUVIO® (nemolizumab-ilt)

To Whom It May Concern:

I am writing this in support of my request to review a denied claim for my patient, [patient name]. On [date of denial], your organization denied this claim for NEMLUVIO, an FDA-approved medication indicated for the treatment of adults with prurigo nodularis (PN).

The reason(s) for denial [is/are] stated as [list reason(s) for the denial from the health insurance plan denial letter.] I disagree with this decision because [reason(s) you disagree with the denial]. This letter [and the attached documentation] provide support for the use of NEMLUVIO for this patient.

Clinical Records		
Patient diagnosis: [Include ICD-10 diagnosis code]		
Disease severity: [Include information such as number of nodules, duration of pruritus, and history or signs of repeated itch-scratch cycle]		
Quality of life measures: [Include information such as patient occupation and impact on daily activities]		

Treatment History		
Drug/dose	Treatment dates	Reason(s) for discontinuation or contraindication

NEMLUVIO is one of only two FDA-approved treatments for PN and has been shown to be safe and effective based on the two OLYMPIA phase 3 trials. In the clinical trials, NEMLUVIO monotherapy is administered every 4 weeks in adults with moderate-to-severe PN, which my patient suffers from. NEMLUVIO showed significant and rapid itch relief, skin clearance, and reductions in sleep disturbance compared to placebo in these trials, which my patient could benefit from.^{1,2}

[Summarize treatment recommendation here].

Given the patient's history, their current condition, and the emerging data of the effects of NEMLUVIO in patients with PN, I believe that treatment of NEMLUVIO with [patient name] is warranted, appropriate, and medically necessary, and the claim should be covered and reimbursed. The totality of the data available to date supports the potential benefit of [treatment/continuing treatment] with NEMLUVIO.

Please feel free to contact me, [HCP name], at [office phone number] for any additional information you may require. We look forward to receiving your timely response and approval of this claim.

Sincerely,

[Physician's name and signature, medical specialty, and contact information]

Attachments: [Include list of supporting information provided with letter such as patient medical records, referenced publications, and/or NEMLUVIO Prescribing Information]

References:

1. NEMLUVIO. Prescribing Information. Galderma Laboratories, L.P.; August 2024.
2. Kwatra SG, et al. *N Engl J Med.* 2023;389(17):1579-1589.

US-NPN-2400023 (08/24)

Scan the QR code to the right or [click here](#) to download the sample letter as a Word document to customize for your patient.

Please see Important Safety Information on page 1 and accompanying Prescribing Information or click here for full [Prescribing Information](#).



Patient Letter

A **Patient Letter** is a document written by the patient to the payer that requests a payer to reconsider its initial decision to deny coverage for NEMLUVIO. These letters describe the impact of disease on life. These letters should be presented in a concise manner while also making as strong an argument as possible.

Please see the following page for a template for a patient letter. This is for informational purposes only and to be used as an example of what may be required or helpful when responding to a request from a patient's payer. Use of this information does not constitute medical or legal advice and does not guarantee reimbursement for coverage. It is not intended to be a substitute for the independent clinical decision of the prescribing health care provider.

Please see Important Safety Information on page 1 and accompanying Prescribing Information or click here for full [Prescribing Information](#).



Patient Letter (cont'd)

[Date]

[Patient's name]
 [Date of birth]
 [Case identification]

SAMPLE LETTER

Re: Appeal of Coverage Denial for NEMLUVIO® (nemolizumab-lito)

To Whom It May Concern:

I am writing to request reconsideration of the denial of coverage of NEMLUVIO, as written by [health care professional name & credentials]. I am [an adult patient/a caregiver of an adult] diagnosed with prurigo nodularis (PN). Your reason(s) for the denial were [list reason(s) for the denial from the health insurance plan denial letter].

After reviewing the denial letter, I maintain that NEMLUVIO is appropriate as written by [healthcare professional name] based upon clinical criteria. Listed below is a summary of the relevant clinical history and personal experience with the disease.

As a [patient with PN/caregiver of a patient with PN], here is information about how PN has personally impacted [my/the patient's] life and why I am requesting coverage for the claim to address ongoing clinical needs of living with the disease:

[Include relevant personal experience with the disease and medical information to support the appeal for coverage of NEMLUVIO. May include the following information:

- Supporting information as requested by the payer in its denial letter
- Diagnostic results confirming the disease
- Treatment history, including name of medications, dates of use, and reason(s) for discontinuation
- Summary of how the disease has impacted the patient's quality of life over time; social dynamics; employment dynamics; personal experience living with the disease, etc.
- Clinical attributes of NEMLUVIO and why the patient needs the medical intervention or medication now]

Based upon [my/the patient's] condition and medical history, I believe coverage for NEMLUVIO is appropriate and medically necessary and the claim should be covered and reimbursed.

If you have any further questions about this matter, please feel free to contact me or my HCP at [patient/caregiver phone number; physician phone number] or via email at [patient/caregiver email address; healthcare provider's email address]. Thank you for your time and consideration. I look forward to your timely approval of my request.

Sincerely,
 [Patient or caregiver's name and signature]
 [Patient or caregiver's contact information]

Attachments: [Include list of supporting information provided with letter such as copy of denial letter, patient medical records, referenced publications, and/or NEMLUVIO Prescribing Information]

US-NPN-2400025 (08/24)

Scan the QR code to the right or [click here](#) to download the sample letter as a Word document to customize for your patient.



Please see Important Safety Information on page 1 and accompanying Prescribing Information or [click here](#) for full **Prescribing Information**.



Commonly Used Codes for NEMLUVIO for the Treatment of PN

Disclaimer: These codes are not an exhaustive list of all possible or required billing and coding options for NEMLUVIO and are not intended to provide reimbursement advice. The HCP is responsible for ensuring accurate and appropriate diagnostic coding to obtain reimbursement. For additional guidance on coding, please refer to the Department of Health and Human Services Evaluation and Management Services Guide available at www.cms.gov.

ICD-10 Diagnosis Code for PN:

ICD-10 codes are diagnostic codes used by HCPs to classify and code all diagnoses, symptoms, and procedures for claims processing.¹³

Coding is a clinical decision; ensure you are coding to the highest level of specificity. The code shown below is only a suggestion and may vary by patient.

ICD-10 Code ⁸	Description ⁸
L28.1	Prurigo nodularis

NDC for NEMLUVIO

An NDC is a unique, 3-segment number that serves as a universal product identifier for a drug.¹⁴

NDCs ¹²	Description ¹²	Dosage Strength ¹²
10-digit code: 0299-6220-15 11-digit code: 00299-6220-15	Prefilled pen (pack of 1 pen)	30 mg/0.49 mL

Electronic data exchange standards usually require the use of an 11-digit NDC. To convert a 10-digit NDC to an 11-digit NDC, a leading zero is added within the sequence of numbers. In this case, the **boldface** zero converts the 10-digit NDC to the 11-digit NDC. Some payers may require each NDC to be listed on the claim. Payer requirements regarding the use of NDCs may vary.

Specialty Distributor

NEMLUVIO is available for physician offices to order through Cencora. Please note that Cencora is our exclusive distribution partner for physicians utilizing the buy & bill model **only**. To set up an account with Cencora, please call customer service at 1-800-746-6273.

Cencora Ordering Information			
Phone Number	Fax	Email	Website
1-800-746-6273	1-800-547-9413	service@asdhealthcare.com	www.asdhealthcare.com/contact-us

Scan the QR code to the right or [click here](#) to access the **Billing and Coding Guide** for NEMLUVIO for additional information.



HCP, health care provider; ICD-10, International Classification of Diseases, Tenth Revision; NDC, National Drug Code; PN, prurigo nodularis.

Please see Important Safety Information on page 1 and accompanying Prescribing Information or [click here](#) for full **Prescribing Information**.



Summary of Support Programs

The Patient Support Program Services will be managed by Galderma Patient Services (GPS) for patients needing to determine coverage for NEMLUVIO and in need of certain support. When patients enroll in GPS for NEMLUVIO, they will have access to support programs including Nurse Navigators, which help to initiate therapy and stay on treatment. On behalf of enrolled patients, the Field Access Manager team will be able to communicate with offices to support patient access.

Support Program	Description
Patient Welcome Kit	A kit designed to provide NEMLUVIO patients with education and resources to help them successfully start therapy.
Quick Start	Treatment-naïve patients will receive their first/loading dose while awaiting PA decision. Available to eligible, commercially insured patients. Patients can receive up to 2 additional refills. If there are further delays in the PA approval process, patients may move to the Bridge Program.
Bridge Program	Prevents a gap in treatment for eligible patients who have a temporary loss of insurance coverage (i.e., change/loss of insurance, delayed re-authorization or exhausted Quick Start supply during pending payer determination). Patients leveraging the Bridge Program may receive free product for up to 2 years while their HCP works with their insurance to reach a coverage determination.
Copay Support	Qualified, commercially insured patients may pay as little as \$0 for their treatment. Patients will be automatically re-enrolled for the following year, if they are still on the same treatment. Reduces or eliminates copays for eligible, commercially insured patients, up to \$15,000 annually.
Patient Assistance Program	Provides access to eligible, uninsured patients or patients whose insurance does not provide adequate coverage and no other programs are available to help the patient.
Injection Education	Educates patients on recommended preparation and administration techniques. May be done in the home, place of convenience, virtually, or telephonically.
Mail Back Sharps Program	For all patients receiving free goods and any other patient who would like a convenient mail-back sharps disposal option.
Nurse Navigator	Nurses available 8:00 AM-8:00 PM EST (Monday-Friday) to help educate patients on NEMLUVIO and about PN. This service is not intended to take the place of your medical guidance and advice—it is for educational purposes only. Patients seeking advice will be referred back to their prescriber.
Product Replacement	Facilitates requesting a replacement dose of NEMLUVIO due to a Product Quality Complaint (PQC), an error during self-administration or by a caregiver, a non-administration incident due to a malfunction of the self-injectable pen or a non-administration issue due to the physical appearance of a product.

HCP, health care provider; PA, prior authorization; PN, prurigo nodularis.

To access these programs, please click the link below:

<https://www.nemluviohcp.com/access-support>

[Terms and Conditions](#)

Please see Important Safety Information on page 1 and accompanying Prescribing Information or click here for full [Prescribing Information](#).



References

1. Academy of Managed Care Pharmacy. Prior authorization. Accessed February 1, 2024. <https://www.amcp.org/about/managed-care-pharmacy-101/concepts-managed-care-pharmacy/prior-authorization>
2. UnitedHealthcare. Dupixent pharmacy prior authorization request form. Accessed January 31, 2024. <https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/a-g/PA-Med-Nec-Dupixent.pdf>
3. West Virginia Department of Health and Human Resources. Prior authorization request form. Accessed January 31, 2024. <https://dhhr.wv.gov/bms/BMS%20Pharmacy/Documents/Drug%20PA%20Criteria/Dupixent%20Criteria%201.1.23.pdf>
4. Highmark. Dupixent prior authorization form. Accessed January 31, 2024. <https://content.highmarkprc.com/Files/Region/PA-DE/Forms/Pharmacy/dupixent.pdf>
5. Cigna Healthcare. Prior authorization policy. Accessed January 31, 2024. https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_420_coveragepositioncriteria_immunologicals_dupixent_pa.pdf
6. Aetna. Dupixent Coverage Policy/Guideline. Accessed January 31, 2024. <https://www.aetnabetterhealth.com/content/dam/aetna/medicaid/pdfs/formulary/guidelines/Dupixent-Aetna-Medicaid-Policy-ua.pdf>
7. CVS/Caremark. Dupixent. Accessed February 1, 2024. https://www.caremark.com/portal/asset/HMSAFaxForm_Dupixent.pdf
8. Centers for Medicare & Medicaid Services. 2024 ICD-10-CM. Accessed March 8, 2024. <https://www.cms.gov/medicare/coding-billing/icd-10-codes/2024-icd-10-cm>
9. Patient Engagement HIT. Drug formulary exclusion lists reduce patient access to treatment. Accessed January 31, 2024. <https://patientengagementhit.com/news/drug-formulary-exclusion-lists-reduce-patient-access-to-treatment>
10. Security Health. Pharmacy utilization management guidelines. Accessed January 31, 2024. <https://www.securityhealth.org/prescription-tools/exception-process>
11. Serve You Rx. Understanding quantity limited. Accessed February 2, 2024. <https://serveyourx.com/wp-content/uploads/2022/01/Understanding-Quantity-Limits-CS0022.pdf>
12. NEMLUVIO. Prescribing Information. Galderma Laboratories, L.P.; August 2024.
13. American Medical Association. ICD-10. Accessed March 15, 2024. <https://www.ama-assn.org/topics/icd-10>
14. United States Food and Drug Administration. National Drug Code database background information. Accessed January 31, 2024. <https://www.fda.gov/drugs/development-approval-process-drugs/national-drug-code-database-background-information>

© 2024 Galderma Laboratories, L.P. All rights reserved. All trademarks are the property of their respective owners. US-NPN-2400005 (08/24)

Please see Important Safety Information on page 1 and accompanying Prescribing Information or click here for full [Prescribing Information](#).